title: Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection.
abstract: We studied 14 patients acutely infected with wild-type HIV, who underwent supervised treatment interruptions after initial antiretroviral treatment including lamivudine. Lamivudine resistance mutations emerged for the first time during supervised treatment interruptions in one patient. Resistance should be monitored in supervised treatment interruptions trials, because mutations may first be detected only after therapy is interrupted.
authors.affiliation: Massachusetts General Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Cecile L
authors.initials: CL
authors.lastname: Tremblay
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Hicks
authors.forename: Lorraine
authors.initials: L
authors.lastname: Sutton
authors.forename: Francoise
authors.initials: F
authors.lastname: Giguel
authors.forename: Theresa
authors.initials: T
authors.lastname: Flynn
authors.forename: Mary
authors.initials: M
authors.lastname: Johnston
authors.forename: Paul E
authors.initials: PE
authors.lastname: Sax
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Walker
authors.forename: Martin S
authors.initials: MS
authors.lastname: Hirsch
authors.forename: Eric S
authors.initials: ES
authors.lastname: Rosenberg
authors.forename: Richard T
authors.initials: RT
authors.lastname: D'Aquila
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D024882:Drug Resistance, Viral / Q000235:genetics*; D015751:Genes, pol / Q000235:genetics*; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D009154:Mutation / Q000235:genetics*; D012367:RNA, Viral / Q000097:blood
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D019259:Lamivudine